The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis.
Yoonjoo KimJeong Suk KohSeong-Dae WooSong-I LeeDa Hyun KangDongil ParkChaeuk ChungIn-Sun KwonJeong Eun LeePublished in: Clinical Medicine Insights. Oncology (2022)
We found the baseline T3 level was associated with both prognosis and the response to ICIs in patients with advanced NSCLC, probably reflecting impaired liver function and systemic inflammation induced by the interaction of T3 with other biomarkers, such as IL-6, ACTH, cortisol, C-peptide, Hb, LDH, and albumin.